3094results about "Dispersion delivery" patented technology

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

Dosage forms, drug delivery systems, and methods related to sustained release of dextromethorphan or improved therapeutic effects are disclosed. Typically, bupropion or a related compound is orally administered to a human being to be treated with, or being treated with, dextromethorphan.

The invention provides a metal polyphenol nanoparticle, a preparation method thereof and an application of the metal polyphenol nanoparticle in preparation of a medicine for treating acute lung injury, the metal polyphenol nanoparticle is formed by self-assembly of metal ions and polyphenol, the metal ions are selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >, and the polyphenol is selected from Mg < 2 + >, Zn < 2 + >, Mn < 2 + > or Cu < 2 + >. The polyphenol is selected from epigallocatechin gallate (EGCG), caffeic acid (CA), chlorogenic acid (CGA), gallic acid (GA) and luteolin (LUT). The metal polyphenol nanoparticles are used for preparing a medicine for treating acute lung injury induced by sepsis, pneumonia, serious trauma or inhalation injury, and the medicine further comprises a pharmaceutically acceptable carrier. The metal polyphenol nanoparticles provided by the invention are simple in preparation process and high in biological safety, polyphenol and metal ions synergistically enhance the anti-inflammatory and antioxidant activity, and the metal polyphenol nanoparticles are superior to the single use of polyphenol or metal ions.

Compositions and methods for administering ketone bodies to a subject include beta-hydroxybutyrate complexed with or coupled to at least one amino acid. The compositions and methods cause one or more of: weight loss, weight maintenance, reduced blood glucose level, maintenance of blood glucose level, increased muscle and physical performance, enhanced metabolic and cellular repair, improved detoxification and gut health, targeted bioavailability, sustained release and controlled absorption, increased metabolic efficiency, enhanced cellular uptake, minimized side effects, multifunctional therapeutics, improved focus, improved energy, improved cognitive function, improved mental acuity, treatment of traumatic brain injury, treatment of diabetes, treatment of neurological disorder, treatment of cancer, treatment of inflammatory condition, appetite suppression, anti-aging effects, anti-glycation effects, treatment of epilepsy, treatment of depression, improved performance, improved muscle mass, improved motor function, increased strength, increased metabolism, increased fat loss, increased fat oxidation, improved body composition, and improved mood.

The invention relates to the field of medicines. Specifically, the invention relates to a voltage-gated calcium channel alpha2delta subunit ligand containing a polycyclic gamma-aminobutyric acid structure as shown in a general formula I, a preparation method of the voltage-gated calcium channel alpha2delta subunit ligand and application of the voltage-gated calcium channel alpha2delta subunit ligand to treatment of chronic neuropathic pain, epilepsy and anxiety. # imgabs0 #

The present invention relates to N-palmitoyl ethanolamide for the treatment of inflammatory pain in combination with a non-steroidal anti-inflammatory drug, to the use of N-palmitoyl ethanolamide (referred to as palmitoyl ethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug for the treatment of inflammatory pain. Specifically, the present invention relates to palmitoyl ethanolamide for use in the treatment of inflammatory pain, in particular non-neurological inflammatory pain, in which palmitoyl ethanolamide is administered in combination or in combination with a non-steroidal anti-inflammatory drug as needed, in which the administration is separate, combined or simultaneous.

The present invention relates to the use of N-palmitoylethanolamide (known as palmitoylethanolamide or PEA) in combination with a non-steroidal anti-inflammatory drug in the treatment of inflammatory pain. In particular, the present invention is directed to palmitoylethanolamide for use in the treatment of inflammatory pain, in particular non-neuropathic inflammatory pain, where palmitoylethanolamide is administered as needed in association or combination with a non-steroidal anti-inflammatory drug, where said administration is separate, combined, or simultaneous.

Provided are methods for delivering lipid nanoparticles (LNPs) to a lung cell of a subject suffering from or at risk for primary ciliary dyskinesia (PCD), wherein the method comprises nebulizing a liquid pharmaceutical composition to generate an aerosolized pharmaceutical composition, and administering the aerosolized pharmaceutical composition to the subject.

The invention discloses a macrophage-targeting inhalable nano material, a preparation method thereof and application of the inhalable nano material in treatment of sepsis myocarditis, and belongs to the technical field of medicines. The nano-material is a nano-liposome, the nano-liposome comprises a mannose modified nano-liposome microsphere, and the mannose modified nano-liposome microsphere comprises a liposome skeleton shell layer, a drug and a targeting layer; the liposome skeleton shell layer comprises soybean lecithin and cholesterol; the medicine comprises quercetin and TPPU (Thermoplastic Polyurethane); and the targeting layer is formed by connecting mannose modified DSPE-PEG2000 to the outer surface of the liposome skeleton shell layer. The nano material can accurately target macrophages at a cardiac inflammation part, has a multi-target-point synergistic effect, is more convenient and faster in administration, remarkably improves the safety and comprehensively improves the treatment effect.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Compositions including dihydromyricetin (DHM) and methods for forming them through hot melt extrusion.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Solid lipid nanoparticles (SLNs) for delivery of bioactive compounds are disclosed. The SLNs comprise a lipid matrix and surfactant layer encapsulating at least one bioactive compound selected from vitamins, minerals, enzymes, algae-derived bioactives, proteins, peptides, amino acids, antioxidants, small synthetic molecules, plant-derived volatile compounds, or botanical extracts. The SLNs exhibit submicron particle size, low polydispersity, and sufficient surface charge to ensure colloidal stability and efficient delivery. In one embodiment, algae-based bioactives, such as phycocyanin or fucoxanthin, are encapsulated using only natural and sustainable lipids and surfactants to improve bioavailability and support environmentally friendly formulations. The SLNs may be formulated for oral, topical, transdermal, injectable, ophthalmic, mucosal, textile, veterinary, or agricultural administration. Applications include human and animal health, functional foods, skincare, nutrient supplementation, and crop treatment. The disclosed SLNs offer a biocompatible and scalable delivery system that protects sensitive compounds, enables sustained release, and enhances absorption across diverse industries.

The present disclosure describes methods of administering N-acetylcysteine (NAC) via intranasal nose-to-brain administration. The effect of intranasal NAC nose-to-brain administration can be monitored using an analytical technique, for example, magnetic resonance spectroscopy (MRS). In some embodiments, intranasal nose-to-brain NAC can be used to treat a condition, for example, a brain injury.

The traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 12 to 15 parts of radix astragali seu hedysari, 12 to 15 parts of radix codonopsis, 10 to 13 parts of semen ziziphi spinosae, 8 to 15 parts of rhizoma chuanxiong, 10 to 15 parts of radix puerariae, 6 to 10 parts of rhizoma atractylodis macrocephalae, 5 to 10 parts of pericarpium citri reticulatae, 5 to 9 parts of ramulus cinnamomi, 3 to 8 parts of herba lycopi and 2 to 6 parts of folium ginkgo. The traditional Chinese medicine composition is prepared according to the principle of monarch, minister, assistant and guide under the guidance of traditional Chinese medicine syndrome differentiation and disease differentiation treatment theories, is mainly used for tonifying qi, promoting blood circulation to remove blood stasis, improving blood circulation and delaying cardiovascular aging, has the effects of soothing the nerves, nourishing sleep and improving the life quality of patients, and is safe in clinical application and free of side effects.

An oral suspension pharmaceutical composition is disclosed for water soluble salts of arylalkanoic acid (NSAID) drugs such as ibuprofen and naproxen. When mixed with glyceryl esters such as glyceryl caprate / caprylate and water, the resulting combination forms a “liquid scaffold” structure that reliably enables the suspension of significant quantities of said arylalkanoic acid drugs. For example, suspensions containing 25% w / w arylalkanoic acid may be obtained using the aforementioned combination. Suspensions comprising further pharmaceutically active agents, in addition to said arylalkanoic acids, may also be prepared. Also disclosed is a binary blend of glyceryl caprate / caprylate and the sodium salt of ibuprofen and a ternary blend of glyceryl caprate / caprylate and the potassium salt of ibuprofen.

The invention discloses a traditional Chinese medicine compound oral preparation for treating male oligoasthenospermia, and belongs to the technical field of traditional Chinese medicine preparations. The rhizoma polygonati processed with wine, the prepared rehmannia root and the like are used for nourishing the liver and kidney to consolidate congenital, the codonopsis pilosula, the astragalus membranaceus and the like are used for invigorating spleen and replenishing qi to complement postnatal, the fried cowherb seed is used for activating blood circulation, and the salted semen plantaginis is used for promoting diuresis, so that the problems of insufficient spermatogenesis and low vitality caused by deficiency of the spleen and the kidney are fundamentally solved. Experiments and clinical researches show that the preparation can significantly improve the sperm quantity, activity and activity rate of oligoasthenospermia model mice and patients, the clinical total effective rate reaches 90%, the pregnancy rate reaches 53.3%, and the curative effect is superior to that of Wuzi Yanzong pills in a control group. The action mechanism covers regulation of blood lipid metabolism, improvement of hypothalamus-pituitary-gonad axis functions, repair of testicular seminiferous tubule structural damage and reduction of lipid deposition, and meanwhile, oxidative stress and inflammatory injury are relieved and spermatogenic cell functions are protected by regulating and controlling a PPAR signal channel and inhibiting molecular pathways such as Cga / Sting mediated cell apoptosis.

The invention belongs to the technical field of health-care food, and particularly relates to a composition and oral drops with the effects of dispelling the effects of alcohol, protecting the liver and relieving hangover as well as a preparation method and application of the composition and the oral drops. The invention provides a composition taking silybin eutectic crystal, curcumin eutectic crystal, ampelopsis grossedentata extract, pyrroloquinoline quinone disodium salt, reduced glutathione, alpha-ketoglutaric acid, vitamin, hericium erinaceus extract, frankincense extract, licorice extract and the like as main active ingredients, and the composition is subjected to scientific formula screening and functional verification, and has the advantages that the composition has the obvious curative effect, and the curative effect is obvious; the traditional Chinese medicine composition can effectively improve the metabolism of ethanol, protect liver and gastric mucosa, and is helpful for relieving hangover-related symptoms such as fatigue, thirst, sleepiness, headache, dry mouth, stomachache, nausea, hypomnesis, inattention and the like.

The present invention provides, among other things, improved pharmaceutical compositions comprising codon-optimized mRNA encoding a peptide or polypeptide encapsulated in a lipid nanoparticle comprising one or more of the cationic lipids that are particularly effective for pulmonary delivery.

The invention belongs to the technical field of traditional Chinese medicine, and particularly relates to a traditional Chinese medicine composition for treating meniere disease membrane hydrolost and a preparation method and application thereof. The traditional Chinese medicine composition is prepared from the following raw material medicines: rhizoma alismatis, rhizoma atractylodis macrocephalae, poria cocos, gastrodia elata, ginger processed pinellia, pericarpium citri reticulatae and fresh ginger. The traditional Chinese medicine composition disclosed by the invention is small in dosage and special in effect, and dialectical compatibility is performed according to the phlegm-dampness theory of traditional Chinese medicine, combined with the pathological basis of the meniere disease and based on the treatment rules of transforming fluid retention, inducing diuresis, tonifying spleen and calming liver, so that the aim of treating both symptoms and root causes is achieved. Animal experiments prove that the traditional Chinese medicine composition can obviously relieve the cochlear hydrops degree of a rat with membranous hydrolost.

Provided herein are pharmaceutical compositions and methods for treating COPD or COPD exacerbations in subjects suffering from, for example, moderate COPD, or subjects with decreased eosinophil concentrations, or are suffering from chronic bronchitis. Also provided herein are methods of increasing trough lung function in subjects suffering from moderate COPD. In some aspects, the compound is in an inhalable pharmaceutical composition.

The invention relates to the technical field of nutritional health-care food, and particularly discloses functional oral liquid capable of tonifying qi and blood and enhancing immunity based on ganoderma lucidum active ingredients and a preparation method. The composition comprises a ganoderma lucidum fermentation stock solution, ginseng, lucid ganoderma, astragalus membranaceus, angelica sinensis, fructus lycii, fructus hippophae, rhizoma polygonati, oyster nano peptide, raspberry and a chitosan oligosaccharide-vitamin E stabilizer. The preparation method comprises the following steps: crushing medicinal materials, performing graded extraction, performing ultrasonic integration with a ganoderma lucidum fermentation stock solution, performing membrane separation and purification, performing gradient vacuum concentration, adding a stabilizer under the protection of nitrogen, stirring, and finally performing nitrogen filling and pasteurization. The composition disclosed by the invention can be used for tonifying qi and blood and regulating immunity, the bioavailability is improved by virtue of synergy of ganoderma lucidum polysaccharide, ganoderma lucidum triterpenes and ginsenoside and an oyster nano peptide-sea buckthorn flavone composite carrier, and efficient retention and synergistic interaction of active ingredients are realized; in addition, low-temperature gradient concentration and mild sterilization are adopted in the preparation method, so that the heating time is shortened, and the quality stability of the product is ensured.

The present invention relates to the pharmaceutical composition comprising Zonisamide and one or more pharmaceutically acceptable excipients and also relates to the process for the preparation of the pharmaceutical composition comprising Zonisamide.

The present invention provides The present invention provides nanoparticles comprising a) a micelle comprising an amphiphilic polymer having a number-average molecular weight (Mn) of 20,000 g / mol or less, and b) at least one peptide comprising at least one T-cell epitope. The invention further provides pharmaceutical compositions comprising these nanoparticles, and uses of the compositions for suppressing specific immune responses.

The present invention relates to a compound for use in a method of treating chronic obstructive pulmonary disease (COPD) in a patient suffering from COPD, which compound is ensifentrine or a pharmaceutically acceptable salt thereof, wherein: the patient is resistant to improvements in lung function; and treating COPD comprises (i) improving the symptoms of COPD in the patient and / or (ii) improving the quality of life of the patient. In some aspects, the compound is in an inhalable pharmaceutical composition.

Provided herein are pharmaceutical compositions and methods for providing blood plasma concentrations of ensifentrine to specific patient group populations including those with modified renal or hepatic impairment.

The present invention relates to a process for producing a sterile liquid pharmaceutical composition suitable for administration by inhalation comprising ensifentrine particles, wherein the process comprises: (a) heating ensifentrine particles at a temperature of from 100° C. to 220° C. to obtain sterile ensifentrine particles; and (b) combining the sterile ensifentrine particles with a sterile liquid vehicle to produce the sterile liquid pharmaceutical composition suitable for administration by inhalation. A process for producing an ampule comprising the sterile liquid pharmaceutical composition is also described.